This early-stage study is testing a new oral medication called TNG908 in people with advanced solid tumors that have a specific genetic deletion called MTAP. The research aims to find the safest dose and see if the drug shows any signs of fighting the cancer. Up to 192 participan…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC